First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma

Clinical trial NCT05188859 · RECRUITING

Trial details

NCT number: NCT05188859
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Mesothelioma, Malignant Mesothelioma, Malignant Pleural Mesothelioma Malignant Advanced

Start date: 2024-09-01
Primary completion: 2026-09-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.